/cloudfront-eu-central-1.images.arcpublishing.com/diarioas/HYNFL4JEORLWXOEFVS3PEPFDJA.jpg)
Covid-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday.
Reuters
Covid-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday.
